Stock Analysis

Angelalign Technology Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

SEHK:6699
Source: Shutterstock

Angelalign Technology (HKG:6699) Full Year 2023 Results

Key Financial Results

  • Revenue: CN¥1.48b (up 16% from FY 2022).
  • Net income: CN¥53.5m (down 75% from FY 2022).
  • Profit margin: 3.6% (down from 17% in FY 2022).
  • EPS: CN¥0.32 (down from CN¥1.28 in FY 2022).
revenue-and-expenses-breakdown
SEHK:6699 Revenue and Expenses Breakdown April 25th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Angelalign Technology Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 4.3%. Earnings per share (EPS) missed analyst estimates by 18%.

The primary driver behind last 12 months revenue was the Mainland China segment contributing a total revenue of CN¥1.33b (90% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to CN¥493.2m (53% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of CN¥68.2m. Explore how 6699's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in Hong Kong.

Performance of the Hong Kong Medical Equipment industry.

The company's shares are up 1.4% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Angelalign Technology.

Valuation is complex, but we're helping make it simple.

Find out whether Angelalign Technology is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.